Stop Doing
Business with Russia
Russia initiated aggression against Ukraine in 2014. On February 24, 2022, it started a full-scale military invasion to the Ukrainian territory. This brutal war and military crimes of Russian troops caused a humanitarian crisis in Ukraine with thousands civilians killed and millions becoming refuges. As a reaction to this act of aggression, many international companies decided to leave the Russian market, while some others continue doing business there as usual. We track such decisions of companies and urge them to stop funding the war.
Hold off investments: company postponing future planned investment/development/marketing while continuing substantive business
Pausing InvestmentsReducing Activities: company scaling back some business operations while continuing others
Scaling BackPause operations: company temporarily curtailing operations while keeping return options open
SuspensionClean Break: the company completely halting Russian engagements or exiting Russia
WithdrawalExit Completed: company sold its business/assets or its part of the business to a local partner and leaved the market or liquidated local entity(ies)
Exit Completed
Italy's Recordati boosted by strong sales in Russia. Italian drug maker Recordati benefited from strong demand in markets such as Turkey and Russia in the first three months of the year, its chief executive said on May 11, 2023 after the company lifted its annual revenue and profit targets. Koremans said that Recordati did not produce any products in Russia but continued to import treatments for rare diseases, as well as prescription drugs for more routine conditions.
No official statement
Group's financials says considers Russia a main market. Revenue and profit skyrocketed in 2022 vs 2021.
No official statement
Continuing business in Russia and exports, increased revenue and profit in 2022 vs 2021.
Chiesi Group plans to maintain operations in the Russian territories, focusing primarily on medical information and disease awareness and ensure access to our therapeutic options. Chiesi Group is however temporarily pausing any new recruitment of patients for all ongoing clinical trials in Russia, though continuing to treat all those already enrolled and ensuring they receive all the therapeutic solutions they need. "Our focus will always remain on our patients, and Chiesi will continue to prioritise uninterrupted access to treatments to patients in Ukraine and Russia and surrounding territories, despite the unstable situation."